Ship · Medable
A top pharma ran a long-term follow-up obesity trial on Medable without an EDC and kept 97% of patients.
The sponsor needed high patient retention in a long-term follow-up trial while staying compliant and cost efficient. Medable's platform, with Total Consent and eCOA and no traditional EDC, was used. The page reports a 97% patient retention rate.
Medable is a digital clinical trial platform used by pharma sponsors for eCOA, eConsent and decentralized trial delivery
This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.
Source
Published by Medable on its own site — read the original case study on medable.com ↗
More like this
Related use cases
- 01A top-10 pharma built three Phase III oncology studies in parallel across 30 countries on Medable's platform.
- 02A top-5 pharma scaled global vaccine mega-trials with Medable's eCOA and AI-assisted study build tools.
- 03ICON and Medable reached 85% eConsent adoption across 1,200+ participants in a menopause study.
- 04A biotech worried older participants would struggle with eCOA, and Medable support delivered over 90% adherence in its vaccine trial.
- 05Transforming Content Operations for 2x Faster Time to Market
- 06Astellas: Breaking Access Barriers with Veeva Compliant Chat